title: 5' region and exon 7 mutations of the TP53 gene in two cases of B-cell prolymphocytic leukemia.
abstract: We previously found that cases of typical B-chronic lymphocytic leukemia (CLL), atypical B-CLL with t(11;14) and mantle cell lymphomas characterized by rapid progression of the disease and resistance to therapy, had mutations of the TP53 gene. In this paper, abnormalities of the TP53 gene were investigated in two cases of prolymphocytic leukemia, one with t(11;14)(q13;q32), evolving from atypical CLL (patient 1), and one presenting as a de novo condition (patient 2). TP53 DNA was investigated by Southern blot and PCR-SSCP analysis, and TP53 expression was investigated by Northern blot analysis and immunocytochemistry. C-MYC and BCL-1/PRAD1 gene expression were also investigated. Restriction enzyme analysis of TP53 DNA in patient 1 showed alteration of fragments including exon I and intron I, and, in both patients, a specific loss of TP53 DNA. In patient 2, PCR direct sequencing showed in exon VII a 9 bp deletion including codons 252-254. In patient 1, TP53 RNA and protein were not found, indicating that the unusual 5' rearrangement has affected TP53 gene expression. By contrast, patient 2 exhibited detectable TP53 RNA and protein. Detectable but weak BCL-1/PRAD1 RNA was present in both patients, whereas C-MYC RNA expression was clearly present only in case 1. The presence of TP53 hemizygous mutations in both patients suggests that TP53 abnormalities may be important in the pathogenesis of prolymphocytic leukemia (PLL), and may possibly account for the frequent resistance to therapy observed in this disease.
authors.affiliation: Centro Interdipartimentale di Biotecnologie-Sezione di Studi Biochimici delle Patologie del Genoma Umano, Università degli Studi, Ferrara, Italy.
authors.forename: C
authors.initials: C
authors.lastname: De Angeli
authors.forename: A
authors.initials: A
authors.lastname: Cuneo
authors.forename: G
authors.initials: G
authors.lastname: Aguiari
authors.forename: M G
authors.initials: MG
authors.lastname: Roberti
authors.forename: N
authors.initials: N
authors.lastname: Piva
authors.forename: S
authors.initials: S
authors.lastname: Moretti
authors.forename: P
authors.initials: P
authors.lastname: Cavazzini
authors.forename: G
authors.initials: G
authors.lastname: Castoldi
authors.forename: L
authors.initials: L
authors.lastname: del Senno
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005091:Exons / Q000235:genetics; D005260:Female; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D015463:Leukemia, Prolymphocytic / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D008297:Male; D012333:RNA, Messenger / Q000032:analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
chemical_list: D012333:RNA, Messenger; D016159:Tumor Suppressor Protein p53